Diazepam (CAS 439-14-5; C16H13ClN2O; relative molecular mass 284.74 g/mol; 7-chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one) is a long-acting 1,4-benzodiazepine supplied as a white or almost white crystalline powder. The veterinary-grade active pharmaceutical ingredient designated Diazepam (Valium, Stesolid) Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is the unformulated drug substance used in licensed veterinary finished-dose manufacturing and in some controlled compounding operations. Valium and Stesolid are trademarked reference product names; the API substance itself is not branded and must comply with the current diazepam monograph of the Ph. Eur., USP, or BP. In aqueous media the compound is practically insoluble, while its ethanol and chloroform solubility supports the co-solvent and granulating-fluid systems used in oral solutions and injectable concentrates. The material is light-sensitive and is packaged in double low-density polyethylene liners inside sealed aluminium drums with desiccant to maintain loss-on-drying and impurity stability during transport.

Despite the phrase “veterinary grade,” diazepam is not a different molecular species from the human-compendial drug substance. The veterinary designation refers to the control strategy, packaging configuration, registration support, controlled-substance handling, and route-specific grade selection available for animal drug product manufacturers rather than to a lower purity or altered identity. The API is compatible with the same pharmacopoeial monograph used by human manufacturers; differences become apparent in the certificate of analysis, residual solvent profile, endotoxin option, and particle-size specification for species-specific dosage forms. It is a regulated starting material rather than a ready-to-administer medicine.

What Critical Release Controls Apply to the Veterinary Drug Substance?

Before release into veterinary manufacturing, each batch is tested against the current compendial monograph and the supplier’s validated specification. Identification is performed by infrared absorption against diazepam chemical reference substance, complemented by reversed-phase HPLC retention time. The melting range is 131–135 °C, which discriminates crystalline diazepam from structurally related compounds. Loss on drying is controlled at ≤0.5% and residue on ignition at ≤0.1%. Assay by HPLC is expressed on the dried basis: 99.0%–101.0% under Ph. Eur. and 98.0%–102.0% under USP. Related substances by liquid chromatography typically limit a specified impurity to ≤0.10%, an unspecified impurity to ≤0.10%, and total impurities to ≤0.30%.

Residual solvents are controlled under VICH GL18 using compendial methods such as Ph. Eur. 2.4.24 or USP <467>. Class 2 solvents such as methanol or dichloromethane are reported and limited, Class 3 solvents are limited by good manufacturing practice, and Class 1 solvents such as benzene are absent by design. Heavy metals or elemental impurities follow Ph. Eur. 2.4.8/USP <231> for heavy metals and, where required, an ICH Q3D-compliant risk assessment. For veterinary parenteral use, the API is not sterile; it should be released with bioburden data and a bacterial endotoxin specification derived from the intended maximum species dose and route. Particle-size distribution is set by the finished-dose requirement: direct-compression tablet and capsule grades commonly require D90 ≤100 µm; injectable and oral-solution grades may require D90 ≤30 µm to match dissolution, filter loading, and content uniformity.

Physicochemical Properties Governing Tablets, Capsules, Powders, Granules, Premixes, and Solutions

At low oral doses of 2 mg, 5 mg, and 10 mg, tablet manufacture is strongly influenced by diazepam’s low aqueous solubility and cohesive powder behavior. A direct-compression process typically uses lactose monohydrate or microcrystalline cellulose as the primary filler, croscarmellose sodium or sodium starch glycolate as disintegrant, and magnesium stearate as lubricant. The API is first passed through a 0.5 mm or 1.0 mm screen to break agglomerates, then mixed with a portion of the filler in a tumble blender. Over-lubrication must be avoided: prolonged blending with magnesium stearate can form a hydrophobic film and reduce dissolution at the 5 mg strength when tested under USP <711> apparatus 2 at 75 rpm. Content uniformity is verified under USP <905> with an acceptance value ≤15.0.

Capsule and powder formulations use geometric trituration because the drug is a low-dose, high-potency compound. A 1:10 or 1:20 trituration or wet granulation step is common to avoid segregation and to control assay variance in finished capsules. Final blend moisture is maintained below 2.0% to reduce hydrolytic degradation and sticking on tablet punches. Granules and medicated premixes are made by low-shear planetary mixing or fluid-bed granulation; the granulating fluid is usually ethanol or a hydroalcoholic solution because water alone does not dissolve the API and can produce uneven distribution. Drying is controlled at 40–50 °C inlet air temperature, and final granules are sieved to 20–60 mesh for uniform metering.

Because premix and oral-powder operations involve dilutions from concentrated API to 0.1%–1.0% w/w working premixes, mixing scale-ups are limited by low-dose content uniformity. A stepwise mixing study with three-point sampling is used to identify dead zones in ribbon or paddle mixers; assay variance between top, middle, and bottom samples should remain within the finished-product acceptance range. For oral solutions, the API is dissolved in a solvent blend such as ethanol/propylene glycol and then filled into amber glass or polyethylene terephthalate containers; light protection and child-resistant closures are mandatory. For injectable solutions, propylene glycol and ethanol co-solvent systems are used because the API will precipitate on direct aqueous dilution. The final solution is filtered through a 0.45 µm prefilter and then a sterilising-grade 0.22 µm filter; filling under nitrogen reduces oxygen-mediated discoloration and protects benzyl alcohol. Adsorption onto polyvinyl chloride administration sets is a known incompatibility, and aqueous infusion dilution is performed only under controlled conditions specified by the finished-product manufacturer.

When Diazepam Is Selected Over Midazolam or Lorazepam in Veterinary Platforms

In veterinary finished-dose selection, diazepam’s longer terminal half-life and active metabolites—nordazepam, temazepam, and oxazepam—distinguish it from midazolam, which is short-acting and water-soluble under acidic conditions, and from lorazepam, which is metabolised by glucuronidation without the same active benzodiazepine metabolites. Diazepam is therefore selected when oral intermittent anxiolysis, skeletal muscle relaxation, or seizure management is desired over a longer observation window. Midazolam is generally used for rapid induction or short procedural sedation, while lorazepam is used for longer hospital-based sedation but requires non-aqueous or inclusion-complex vehicles. The high lipid solubility of diazepam supports rapid central nervous system penetration after intravenous dosing but also leads to redistribution into adipose tissue and potential accumulation in obese or geriatric veterinary patients. Published data for species-specific clearance in some veterinary target species is limited, and dosing intervals must be derived from finished-product labels rather than from in vitro receptor affinity alone.

Regulatory Dossiers Must Align Residual Solvent Controls Across USP, Ph. Eur., and VICH GL18

Across USP, Ph. Eur., and VICH GL18 submissions, manufacturing documentation for diazepam veterinary API should reference current general chapters for residual solvents, elemental impurities, and microbiological quality. The API dossier is filed under the drug master file or veterinary master file in the destination jurisdiction and includes a table of analytical methods with validation summaries. Residual solvent control is not limited to the API supplier; finished-product manufacturers must also demonstrate that co-solvent residues in injectable and oral-solution formulations are controlled after terminal sterilisation or aseptic processing. VICH GL18 mirrors ICH Q3C for residual solvents and should be used for veterinary submissions; for injectables, the finished product must meet the pharmacopoeial limit for bacterial endotoxins and the relevant particulate matter test such as USP <788> or Ph. Eur. 2.9.19.

Because diazepam is a controlled substance in many markets—Schedule IV under the US Controlled Substances Act and similar psychotropic scheduling elsewhere—import, export, and reconciliation records must be maintained. The API should be stored in a secure, bond-controlled area at controlled room temperature 15–25 °C and protected from light. Use of the API in veterinary compounding or clinical trial formulations requires the responsible veterinarian or pharmacist to verify the formula against current evidence; the API itself is not approved for direct lay administration.

During storage above 60% relative humidity, the API should remain in sealed aluminium drums and should be opened only under low-humidity conditions. Because diazepam is light-sensitive, long-term exposure to direct ultraviolet light can produce discoloration and increase related substances. Reconstitution of injectable concentrates or dilution of oral solutions should be performed only with the solvent system defined in the finished-product dossier, as aqueous dilution can cause precipitation and inconsistent dose delivery. The veterinary-grade API is not a sterile product, is not intended for direct injection, and is not interchangeable with a finished injection vial without further sterile manufacture and quality release.